GlassScriptPhysician profile
Kayla Dyer
NPI 1992257323
$5,857.85
in general payments reported to CMS, 2019-2025
26 companies · $3,728 in 2025
The $3,728 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $482 · 2022: $412 · 2023: $305 · 2024: $932 · 2025: $3,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,964.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,585.21 | 2021-2025 | |
| Janssen Biotech, INC. | $543.06 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $483.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.33 | 2021-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $243.51 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $194.20 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $162.94 | 2024-2025 | Ibsrela |
| Celgene Corporation | $159.82 | 2022-2024 | Sotyktu |
| Qol Medical, LLC | $153.69 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $152.62 | 2024-2025 | Entyvio |
| Evoke Pharma, INC. | $148.32 | 2023-2025 | Gimoti |
| Genzyme Corporation | $125.51 | 2025 | |
| Aimmune Therapeutics, INC. | $88.61 | 2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $78.76 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $70.99 | 2024-2025 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $53.07 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $46.66 | 2025 | Voquezna |
| Novo Nordisk INC | $46.06 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $40.55 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $35.67 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $24.51 | 2024 | Terlivaz |
| Lilly USA, LLC | $18.31 | 2025 | Omvoh |
| Boston Scientific Corporation | $17.30 | 2021 | |
| Braintree Laboratories, INC. | $15.90 | 2021 | |
| Merck Sharp & Dohme LLC | $15.22 | 2024 | Dificid |
| Redhill Biopharma INC. | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.